Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 10, 2022Clinical TherapeuticsOpen Access

Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study

View Full Paper
Ask AI
Bookmark
Share

Authors

WSWinnie SohnPWPeter WinkleJNJoel Neutel

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sohn et al. (2022) studied this question.

synapsesocial.com/papers/6a0f0366a14f152feafa26achttps://doi.org/10.1016/j.clinthera.2022.07.008
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lipoprotein(a) Levels in the Japanese Population: Influence of Age and Sex, and Relation to Atherosclerotic Risk Factors: The Jichi Medical School Cohort Study1995 · 75 citations
  2. 2High-Risk Atherosclerotic Cardiovascular Disease in a Real-World Employed Japanese Population: Prevalence, Cardiovascular Event Rates, and Costs2015 · 44 citations
  3. 3Use of a Reference Material Proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to Evaluate Analytical Methods for the Determination of Plasma Lipoprotein(a)2000 · 318 citations
  4. 4Lipoprotein(a) and Coronary Heart Disease2000 · 939 citations
  5. 5Lipoprotein(a) and Cardiovascular Diseases ― Revisited ―2020 · 95 citations